Do you want to read an article? Please log in or register.
Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)
Lung, Respiratory and Thoracic Cancer
Related content
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Barsouk A, Elghawy O, Watts A, Reed-Guy L, Tompkins W, Chandrasekhara K, Grady CB, Iams W, Sun F, Liu G, Patel D, Nieva JJ, Marrone KA, Velcheti V, Liu SV, Patil T, Weiss J, Schwartzman W, Villaruz LC, Hermann A, Aisner DL, Hwang WT, Camidge DR, Sun L, Singh AP, Cohen RB, Aggarwal C, Langer CJ, Marmarelis ME
doi: 10.1016/j.lungcan.2025.108551
Lung, Respiratory and Thoracic Cancer
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset
Lung Cancer
Cho BC, Hayashi H, Lee JS, Lee SH, Danchaivijitr P, Cheng Y, Liu B, Alip A, Xiong H, How SH, Chang GC, Yang JC, Yoshioka H, Nahit Şendur MA, Prabhash K, Azuma K, Lee YG, Lin CC, Matsumoto S, Sunpaweravong P, Xia Y, Martinez M, Bauml JM, Sethi S, Lu S
doi: 10.1016/j.lungcan.2025.108496
Lung, Respiratory and Thoracic Cancer
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer
J Clin Oncol
He J, Tsuboi M, Weder W, Chen KN, Hochmair MJ, Shih JY, Lee SY, Lee KY, Nhung NV, Saeteng S, Liu L, Xing L, Gia NH, Murakami S, Han Y, Saavedra MP, Yoon SH, Teixeira CHA, Escriu C, Martinez-Marti A, Blakely CM, Yatabe Y, Dacic S, Rukazenkov Y, Huang X, Dayal A, Chaft JE, NeoADAURA Investigators
doi: 10.1200/JCO-25-00883
Lung, Respiratory and Thoracic Cancer
Clinical factors and molecular co-alterations impact outcomes in patients receiving first-line osimertinib for EGFR-mutated non-small cell lung cancer
Lung Cancer
Sun F, Banwait MK, Singhal S, Herrmann A, Piotrowska Z, Yun K, Bazhenova L, Ullah AT, Guo EW, Wakelee HA, Neal JW, Das MS, Ramchandran KJ, Roy M, Diehn M, Myall NJ
doi: 10.1016/j.lungcan.2025.108747
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Clinical Outcomes of Compound EGFR Mutations in Non-Small Cell Lung Cancer: A National, Retrospective, Multicenter Study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Atlagh L, Toublanc AC, Roch B, Marinello A, Ruuth-Praz J, Cousin S, Chouaid C, Basset C, Evrard S, Duruisseaux M, Girard N, Durand K, Mazières J, Brindel A
doi: 10.1016/j.cllc.2025.06.005
Lung, Respiratory and Thoracic Cancer
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
Lancet
Lu S, Wang J, Yang N, Lv D, Chen L, Wu L, Li X, Sun L, Yu Y, Jin B, Yang L, Guo Y, Xu H, Yi T, Zeng A, Dong X, Chen J, Wang Z, Niu H, Cheng Y, Pan P, Deng P, Pan H, Min X, Bai J, Liu L, Zhang T, Li J, Fan S, Shi MM, Mok T, Su W, SACHI Study Group
doi: 10.1016/S0140-6736(25)01811-2
Lung, Respiratory and Thoracic Cancer
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study
Lung Cancer
Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y
doi: 10.1016/j.lungcan.2025.108748
Lung, Respiratory and Thoracic Cancer
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study
Eur J Cancer
Wislez M, Mascaux C, Cadranel J, Thomas QD, Ricordel C, Swalduz A, Pichon E, Veillon R, Gounant V, Rousseau-Bussac G, Madroszyk A, Daniel C, Ravoire M, Metivier AC, Fournel P, Missy P, Morin F, Guisier F, Westeel V
doi: 10.1016/j.ejca.2025.115301
Lung, Respiratory and Thoracic Cancer
Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancers
Lung Cancer
Agrawal P, Rotow J, Rocco G, Travis W, Ortiz E, Scalabrino R, LoPiccolo J, Facchinetti F, Kris MG, Yu HA, Jones D, Chaft JE
doi: 10.1016/j.lungcan.2025.108795